Journal
INTERNATIONAL JOURNAL OF ONCOLOGY
Volume 48, Issue 1, Pages 281-292Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/ijo.2015.3257
Keywords
theaflavin-3, 3 '-digallate; tumor angiogenesis; Akt pathway; c-Myc; Notch-1 pathway
Categories
Funding
- West Virginia Higher Education Policy Commission/Division of Science Research
- NIH from the National Center for Research Resources [P20RR016477]
- National Institute for General Medical Sciences (NIGMS) [P20GM103434]
Ask authors/readers for more resources
Theaflavin-3, 3'-digallate (TF3) is a black tea polyphenol produced from polymerization and oxidization of the green tea ployphenols epicatechin gallate and (-)-epigallocate-chin-3-gallate (EGCG) during fermentation of fresh tea leaves. TF3 has been reported to have anticancer properties. However, the effect of TF3 on tumor angiogenesis and the underlying mechanisms are not clear. In the present study, TF3 was verified to inhibit tumor angiogenesis. Compared with EGCG, TF3 was more potent. TF3 inhibited human ovarian carcinoma OVCAR-3 cell-induced angiogenesis in human umbilical vein endothelial cell model and in chick chorioallantoic membrane model. TF3 reduced tumor angiogenesis by downregulating HIF-1 alpha and VEGF. One of the mechanisms was TF3 inactivated Akt/mTOR/p70S6K/4E-BP1 pathway and Akt/c-Myc pathway. Besides, TF3 suppressed the cleavage of Notch-1, subsequently decreased the expression of c-Myc, HIF-1 alpha and VEGF, and finally the impaired cancer cells induced angiogenesis. Nevertheless, TF3 did not have any influence on the MAPK pathways. Taken together, these findings suggest that TF3 might serve as a potential anti-angiogenic agent for cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available